NY-DOOLA
12.5.2022 14:32:10 CEST | Business Wire | Press release
doola announced today that they have launched a banking product for global businesses that will allow founders to open a US bank account, remotely, from any continent, with no US Social Security Number required. Founders globally can now register an LLC, DAO LLC, or C Corp through doola, get an EIN (employer identification number) from the IRS with doola, and open a US bank account with doola. It doesn’t stop there: doola also provides ongoing compliance with the state and IRS to keep companies compliant, making doola an all-in-one platform for founders to launch, maintain and grow their US business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509006242/en/
doola's banking product will include a business checking account along with domestic and international wire transfers, virtual cards, a physical debit card that is mailed to founders anywhere in the world, tools and features to seamlessly integrate with your US entity, and more.
“ For any business, whether it's a venture-backed SaaS startup with a Delaware C Corp or a solopreneur bootstrapping an e-commerce business, having a trustworthy, stable, and scalable banking + payments stack is critical. Through doola, international founders can seamlessly access the US financial ecosystem, including US banking, US payment solutions, US venture capital, and more,” said Jacqueline Reses , an investor in doola, Chairman of the Economic Development Council at Federal Reserve Bank of San Francisco, and Former Head of Square Capital.
Arjun Mahadevan, CEO, doola said, “From day 1, we’ve known that doola is not a formation service. We’re a fintech company. Founders globally don’t actually want a company; they want a way to accept payments globally in the US dollar, or accept investment from US investors. doola Banking makes our platform the fastest way to go from formation to accepting your first payment/deposit globally. Why? Because we do it all in-house. It’s click button, get company + EIN + bank account, and ongoing compliance including state + IRS filings are taken care of. As our customers like to say, we’re a Business-in-a-Box.”
About doola
doola (formerly StartPack, YCombinator S20) helps global web2 and web 3 entrepreneurs form U.S. LLCs, C Corps, and DAO LLCs by supporting customers through the incorporation process so they can confidently collect payments, build credibility, stay legal, and make more money. doola provides company formation, an EIN, a U.S. address and bank account, access to U.S. payments, a free tax consultation, U.S. tax support, a phone number, $50,000 in startup perks, and more. Today, hundreds of companies have launched with doola, and these founders didn't need a U.S. social security number to benefit from doola's products and services. The company is led by Arjun Mahadevan, a former Growth Product Manager at Dropbox, who is a U.S. immigrant and JP Pincheira, a full stack engineer who is a foreign founder from Chile. (HQ: New York City)
doola is a financial technology company and is not a bank. Banking services provided by Piermont Bank; Member FDIC. The doola Visa® Debit Card is issued by Piermont Bank pursuant to a license from Visa U.S.A. Inc. and may be used everywhere Visa debit cards are accepted.
Related Links
Website: https://www.doola.com/banking
Twitter: https://twitter.com/doolaHQ
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509006242/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom